Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells

Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells

VJHemOnc

1 year
52 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The use of checkpoint inhibitors in multiple myeloma (MM) is an exciting area. The data from two KEYNOTE studies examining this are discussed here by Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA: KEYNOTE-185 (NCT02579863), investigating pembrolizumab in the frontline setting; and KEYNOTE-183 (NCT02576977), which looked at prembrolizumab plus pomalidamide and dexamethasone in the relapsed/refractory setting. Prof. Raje highlights the factors that must be taken into account when using checkpoint inhibitors in MM. Lastly, she covers the trial (NCT01729091) of a umbilical cord blood?derived NK-cell therapy for MM patients undergoing high dose chemotherapy and auto?HSCT.
Up Next Autoplay